Edición/Edição: 1ª Autores:Bengt Källén Editorial:Springer ISBN: 9783319406961 Formato: Rústica/Paperback Nº volumenes: 1 Páginas: 299 Año publicación/Ano de publicação: 2016 Disponibilidad/Disponibilidade: 15 días Precio/Preço
:115,49 €109,71 €(114,10€ iva incluído)
(Sea el primero en opinar
) ¿Vas a pedir más de 5 productos? Escríbenos, te enviaremos presupuesto ajustado, envíanos mail
This book addresses methodological aspects of epidemiological studies on maternal drug use in pregnancy. Discussing the existing sources of error and how they can produce incorrect conclusions, it examines various epidemiological techniques and assesses their strengths and weaknesses. These refer both to the identification of outcomes (with special emphasis on congenital malformations) and to the types of exposure (drug use).
Further, the book discusses the problem of confounding and how to handle it, and provides a simple introduction to statistics. Special situations, e.g. different types of parental exposure, are examined. Lastly, the book discusses pharmacovigilance and the information problem, concluding with a short list of aspects to consider when one wants to evaluate a published paper in the field.
Though the book is primarily intended for pharmacologists, gynecologists and obstetricians, it will benefit all doctors working in perinatal care.
Bengt Källén is a professor emeritus of embryology at Lund University in Sweden and head of the Tornblad Institute for embryology. He has been working in birth defect epidemiology since the 1960s, and served from 1964 to 2015 as a consultant at the National Board of Health and Welfare in Stockholm, mainly focusing on the national registration of congenital malformations and analyses of reproduction outcome after exposure to various influences, including drugs. He is one of the founders of the Swedish Register of Congenital Malformations, and of the International Clearinghouse for Birth Defects Monitoring Systems. He has published ca. 400 scientific papers, including numerous articles on congenital malformations, the effects of maternal drug use during pregnancy, and in vitro fertilization.